ERYTECH to Host Second Quarter 2018 Conference Call and Business Update
September 06, 2018 01:30 ET
|
Erytech Pharma S.A.
LYON, France, Sept. 06, 2018 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext Paris: ERYP - Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating...
ERYTECH to Webcast Presentation at the Jefferies Global Healthcare Conference
May 30, 2018 01:30 ET
|
Erytech Pharma S.A.
LYON, France, May 30, 2018 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext Paris:ERYP) (Nasdaq:ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating...
ERYTECH Reports First Quarter 2018 Financial Results and Provides Business Update
May 14, 2018 16:30 ET
|
Erytech Pharma S.A.
Finalized Phase 3 trial design for eryaspase in second line pancreatic cancer; on track for expected start of patient enrollment in Q3Selected triple-negative breast cancer as the next solid tumor...
ERYTECH annonce le dépôt de son Document de Référence 2017 et de son Form 20-F 2017
April 24, 2018 16:30 ET
|
Erytech Pharma S.A.
LYON, France, 24 avr. 2018 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext Paris:ERYP) (Nasdaq:ERYP), société biopharmaceutique de stade clinique développant à partir de sa plateforme propriétaire...
ERYTECH Announces Filing of 2017 “Document de Référence” and 2017 Annual Report on Form 20-F
April 24, 2018 16:30 ET
|
Erytech Pharma S.A.
LYON, France, April 24, 2018 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext Paris:ERYP) (Nasdaq:ERYP), the clinical-stage biopharmaceutical company developing innovative therapies for severe forms of...
ERYTECH to Present Results from Phase I Trial of eryaspase in ALL and New Pre-clinical Data at AACR 2018
April 12, 2018 01:30 ET
|
Erytech Pharma S.A.
LYON, France, April 12, 2018 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext Paris:ERYP) (Nasdaq:ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating...